<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/omet2017135-40</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-8136</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Научные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original studies</subject></subj-group></article-categories><title-group><article-title>Адипокины, миокины и цитокины при раке эндометрия: связь с фенотипом избыточной массы тела и клинико-морфологическими особенностями опухоли</article-title><trans-title-group xml:lang="en"><trans-title>Adipokines, myokines and cytokines in endometrial cancer patients: relations to obesity phenotype of excessive body mass and features of the tumor</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5112-3372</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Берштейн</surname><given-names>Лев Михайлович</given-names></name><name name-style="western" xml:lang="en"><surname>Berstein</surname><given-names>Lev M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, главный научный сотрудник лаборатории онкоэндокринологии</p></bio><bio xml:lang="en"><p>ScD, professor</p></bio><email xlink:type="simple">levmb@endocrin.spb.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Порошина</surname><given-names>Татьяна Евгеньевна</given-names></name><name name-style="western" xml:lang="en"><surname>Poroshina</surname><given-names>Tatyana E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.б.н., биолог - врач КЛД лаб. эндокринологии</p></bio><bio xml:lang="en"><p>PhD</p></bio><email xlink:type="simple">te_poroshina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васильев</surname><given-names>Дмитрий Алексеевич</given-names></name><name name-style="western" xml:lang="en"><surname>Vasilyev</surname><given-names>Dmitry A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н.</p></bio><bio xml:lang="en"><p>ScD</p></bio><email xlink:type="simple">dvasilyev@hotmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>&lt;p&gt;ФГБУ &amp;laquo;Научно-исследовательский институт онкологии имени Н.Н. Петрова&amp;raquo; Министерства здравоохранения Российской Федерации&lt;/p&gt;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>&lt;p&gt;N.N. Petrov Research Institute of Oncology&lt;/p&gt;</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>&lt;p&gt;ФГБУ &amp;laquo;Научно-исследовательский институт онкологии имени Н.Н. Петрова&amp;raquo; Министерства здравоохранения Российской Федерации&lt;/p&gt;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>&lt;p&gt;N.N. Petrov Research Institute of Oncologyy&lt;/p&gt;</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>13</day><month>06</month><year>2017</year></pub-date><volume>14</volume><issue>1</issue><fpage>35</fpage><lpage>40</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Берштейн Л.М., Порошина Т.Е., Васильев Д.А., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Берштейн Л.М., Порошина Т.Е., Васильев Д.А.</copyright-holder><copyright-holder xml:lang="en">Berstein L.M., Poroshina T.E., Vasilyev D.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/8136">https://www.omet-endojournals.ru/jour/article/view/8136</self-uri><abstract><p>Цель исследования – изучить содержание в сыворотке крови ряда известных адипо-, мио- и цитокинов и сопоставить полученные данные с фенотипом избыточной массы тела и характеристиками опухолевого процесса у нелеченых больных раком эндометрия (РЭ).</p><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование были включены 88 больных со средним возрастом 60,08±0,67 лет и средним индексом массы тела (ИМТ) 32,90±0,83. Больные подвергались антропометрии и анализу лабораторных показателей, в частности, уровня лептина, адипонектина, оментина, префилина (Pref-1), миостатина, ирисина, а также инсулинемии и индекса инсулинорезистентности (HOMA-IR). По совокупности антропометрических и лабораторных данных подразделяли больных с избыточной массой тела (&gt;25,0) на имеющих ее «стандартный» (С) и условно «метаболически здоровый» (МЗ) фенотип.</p></sec><sec><title>Результаты</title><p>Результаты. Уровни инсулина, лептина и адипонектина в сыворотке крови больных РЭ ассоциированы с величиной ИМТ и демонстрируют достоверные различия между больными групп С и МЗ. Уровни префилина, миостатина и ИЛ-6 не связаны с нарастанием величины ИМТ, но тоже достоверно различаются у больных с С и МЗ фенотипом избыточной массы тела. Для уровней ирисина, оментина и ФНО-альфа не свойственна зависимость как от величины ИМТ, так и от принадлежности к группам С или МЗ. С менее благоприятной степенью дифференцировки опухоли связан уровень оментина в крови (группа МЗ), а с более продвинутой стадией заболевания – уровень ИЛ-6 (все больные и группа С).</p></sec><sec><title>Заключение</title><p>Заключение. Циркулирующие в крови адипо-, мио- и цитокины различаются при раке эндометрия характером своих связей с ИМТ, «стандартным» или «метаболически здоровым» вариантом его избытка и особенностями опухолевого процесса, что в совокупности может иметь и прикладное значение.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study serum content of a number of known adipokines, myokines and cytokines and compare obtained data with overweight phenotype and characteristics of tumor in untreated patients with endometrial cancer (EC)</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study included 88 patients with a mean age 60.08±0.67 years and a mean body mass index (BMI) 32.90±0.83. Patients were subjected to anthropometry and analysis of laboratory parameters, including serum level of leptin, adiponectin, omentin, prefilin (Pref-1), myostatin, irisin, IL-6 as well as insulinemia and insulin resistance index (HOMA-IR). On the basis of combination of anthropometric and laboratory data patients with overweight (BMI &gt;25.0) were subdivided into the groups with "standard" (S) and conditionally "metabolically healthy" (MH) phenotype.</p></sec><sec><title>Results</title><p>Results. Levels of leptin, insulin and adiponectin in the serum of patients with EC are associated with BMI value and demonstrate significant differences between S and MH groups. Levels of prefilin, myostatin, and IL-6 are not associated with an increase in BMI, but are also different in patients with S and MH phenotype of overweight.For levels oа irisin, omentin, and TNF-alphathere is no peculiar dependence both, the BMI, and of belonging to a group with S or MH phenotype. Omentin level in the serum is associated with less favorable tumor differentiation (MH group), while IL-6 level – with a more advanced stage of the tumor (all patients and group S).</p></sec><sec><title>Conclusion</title><p>Conclusion. Adipokines, myokines and cytokines circulating in blood of EC patients vary in their connections with BMI or with "standard" or "metabolically healthy" phenotype of its excess. They vary also in relation to EC features, which in sum may have practical importance.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>лептин</kwd><kwd>адипонектин</kwd><kwd>оментин</kwd><kwd>префилин (преадипоцитарный фактор-1)</kwd><kwd>миостатин</kwd><kwd>ирисин</kwd><kwd>фактор некроза опухоли-альфа</kwd><kwd>интерлейкин-6</kwd><kwd>фенотип избыточной массы тела</kwd><kwd>рак эндометрия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>leptin</kwd><kwd>adiponectin</kwd><kwd>omentin</kwd><kwd>prefilifin (Pref-1)</kwd><kwd>myostatin</kwd><kwd>irisin</kwd><kwd>tumor necrosis factor-alpha</kwd><kwd>interleukin-6</kwd><kwd>excessive body mass phenotype</kwd><kwd>endometrial carcinoma</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">частичная поддержка РФФИ (грант 15-04-00384)</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sheikh MA, Althouse AD, Freese KE, et al. USA Endometrial Cancer Projections to 2030: should we be concerned? Future Oncology. 2014;10(16):2561-2568. doi: 10.2217/fon.14.192.</mixed-citation><mixed-citation xml:lang="en">Sheikh MA, Althouse AD, Freese KE, et al. USA Endometrial Cancer Projections to 2030: should we be concerned? Future Oncology. 2014;10(16):2561-2568. doi: 10.2217/fon.14.192.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecologic Oncology. 2009;114(1):121-127. doi: 10.1016/j.ygyno.2009.03.039.</mixed-citation><mixed-citation xml:lang="en">Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecologic Oncology. 2009;114(1):121-127. doi: 10.1016/j.ygyno.2009.03.039.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Obesity and Age at Diagnosis of Endometrial Cancer. Obstetrics &amp; Gynecology. 2014;124(2, PART 1):300-306. doi: 10.1097/aog.0000000000000381.</mixed-citation><mixed-citation xml:lang="en">Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Obesity and Age at Diagnosis of Endometrial Cancer. Obstetrics &amp; Gynecology. 2014;124(2, PART 1):300-306. doi: 10.1097/aog.0000000000000381.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. International Journal of Obesity. 2008;32(9):1431-1437. doi: 10.1038/ijo.2008.102.</mixed-citation><mixed-citation xml:lang="en">Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. International Journal of Obesity. 2008;32(9):1431-1437. doi: 10.1038/ijo.2008.102.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Byers T, Sedjo RL. Body fatness as a cause of cancer: epidemiologic clues to biologic mechanisms. Endocrine Related Cancer. 2015;22(3):R125-R134. doi: 10.1530/erc-14-0580.</mixed-citation><mixed-citation xml:lang="en">Byers T, Sedjo RL. Body fatness as a cause of cancer: epidemiologic clues to biologic mechanisms. Endocrine Related Cancer. 2015;22(3):R125-R134. doi: 10.1530/erc-14-0580.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Берштейн Л.М. Гетерогенность ожирения и рак: потенциальная роль бурой жировой ткани. // Вопросы онкологии. – 2012. –Т. 58. – №4. – С.464-472. [Bershtein LM. Geterogennost' ozhireniya i rak: potentsial'naya rol' buroy zhirovoy tkani. Voprosy onkologii. 2012; 58 (4): 464-472. (in Russ.)].</mixed-citation><mixed-citation xml:lang="en">Берштейн Л.М. Гетерогенность ожирения и рак: потенциальная роль бурой жировой ткани. // Вопросы онкологии. – 2012. –Т. 58. – №4. – С.464-472. [Bershtein LM. Geterogennost' ozhireniya i rak: potentsial'naya rol' buroy zhirovoy tkani. Voprosy onkologii. 2012; 58 (4): 464-472. (in Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Berstein LM. Insulinemia, heterogeneity of obesity and the risk of different types of endometrial cancer: existing evidence. Expert Review of Endocrinology &amp; Metabolism. 2016;11(1):51-64. doi: 10.1586/17446651.2016.1128325.</mixed-citation><mixed-citation xml:lang="en">Berstein LM. Insulinemia, heterogeneity of obesity and the risk of different types of endometrial cancer: existing evidence. Expert Review of Endocrinology &amp; Metabolism. 2016;11(1):51-64. doi: 10.1586/17446651.2016.1128325.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Andres R. Effect of obesity on total mortality. Int J Obes. 1980;4(4):381-386.</mixed-citation><mixed-citation xml:lang="en">Andres R. Effect of obesity on total mortality. Int J Obes. 1980;4(4):381-386.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sims EAH. Characterization of the syndromes of obesity, diabetes mellitus and obesity. Baltimore, London: Williams&amp; Wilkins.1982.</mixed-citation><mixed-citation xml:lang="en">Sims EAH. Characterization of the syndromes of obesity, diabetes mellitus and obesity. Baltimore, London: Williams&amp; Wilkins.1982.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Karelis AD, St-Pierre DH, Conus F, et al. Metabolic and Body Composition Factors in Subgroups of Obesity: What Do We Know? The Journal of Clinical Endocrinology &amp; Metabolism. 2004;89(6):2569-2575. doi: 10.1210/jc.2004-0165.</mixed-citation><mixed-citation xml:lang="en">Karelis AD, St-Pierre DH, Conus F, et al. Metabolic and Body Composition Factors in Subgroups of Obesity: What Do We Know? The Journal of Clinical Endocrinology &amp; Metabolism. 2004;89(6):2569-2575. doi: 10.1210/jc.2004-0165.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">van Vliet-Ostaptchouk JV, Nuotio M-L, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocrine Disorders. 2014;14(1). doi: 10.1186/1472-6823-14-9.</mixed-citation><mixed-citation xml:lang="en">van Vliet-Ostaptchouk JV, Nuotio M-L, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocrine Disorders. 2014;14(1). doi: 10.1186/1472-6823-14-9.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Романцова Т.И., Островская Е.В. Метаболически здоровое ожирение: дефиниции, протективные факторы, клиническая значимость. // Альманах клинической медицины. – 2015. – № Спецвыпуск 1. – С. 75–86. [Romantsova TI, Ostrovskaja EV. Metabolicheski zdorovoe ozhirenie: definitsii, protektivnye faktory, klinicheskaya znachimost'. Al'manakh klinicheskoy meditsiny 2015;1S:75-86. (in Russ.)].</mixed-citation><mixed-citation xml:lang="en">Романцова Т.И., Островская Е.В. Метаболически здоровое ожирение: дефиниции, протективные факторы, клиническая значимость. // Альманах клинической медицины. – 2015. – № Спецвыпуск 1. – С. 75–86. [Romantsova TI, Ostrovskaja EV. Metabolicheski zdorovoe ozhirenie: definitsii, protektivnye faktory, klinicheskaya znachimost'. Al'manakh klinicheskoy meditsiny 2015;1S:75-86. (in Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bell JA, Hamer M, Sabia S, et al. The Natural Course of Healthy Obesity Over 20 Years. Journal of the American College of Cardiology. 2015;65(1):101-102. doi: 10.1016/j.jacc.2014.09.077.</mixed-citation><mixed-citation xml:lang="en">Bell JA, Hamer M, Sabia S, et al. The Natural Course of Healthy Obesity Over 20 Years. Journal of the American College of Cardiology. 2015;65(1):101-102. doi: 10.1016/j.jacc.2014.09.077.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Rothman KJ. BMI-related errors in the measurement of obesity. International Journal of Obesity. 2008;32:S56-S59. doi: 10.1038/ijo.2008.87.</mixed-citation><mixed-citation xml:lang="en">Rothman KJ. BMI-related errors in the measurement of obesity. International Journal of Obesity. 2008;32:S56-S59. doi: 10.1038/ijo.2008.87.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis. Public Health. 2015;129(7):872-880. doi: 10.1016/j.puhe.2015.04.017.</mixed-citation><mixed-citation xml:lang="en">Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis. Public Health. 2015;129(7):872-880. doi: 10.1016/j.puhe.2015.04.017.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. doi: 10.1007/bf00280883.</mixed-citation><mixed-citation xml:lang="en">Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. doi: 10.1007/bf00280883.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2013;45(1):28-36. doi: 10.1007/s12020-013-9973-3.</mixed-citation><mixed-citation xml:lang="en">Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2013;45(1):28-36. doi: 10.1007/s12020-013-9973-3.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kavalkova P, Touskova V, Roubicek T, et al. Serum Preadipocyte Factor-1 Concentrations in Females with Obesity and Type 2 Diabetes Mellitus: The Influence of Very Low Calorie Diet, Acute Hyperinsulinemia, and Fenofibrate Treatment. Hormone and Metabolic Research. 2013;45(11):820-826. doi: 10.1055/s-0033-1353210.</mixed-citation><mixed-citation xml:lang="en">Kavalkova P, Touskova V, Roubicek T, et al. Serum Preadipocyte Factor-1 Concentrations in Females with Obesity and Type 2 Diabetes Mellitus: The Influence of Very Low Calorie Diet, Acute Hyperinsulinemia, and Fenofibrate Treatment. Hormone and Metabolic Research. 2013;45(11):820-826. doi: 10.1055/s-0033-1353210.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin Is Expressed and Produced by Human Muscle and Adipose Tissue in Association With Obesity and Insulin Resistance. The Journal of Clinical Endocrinology &amp; Metabolism. 2013;98(4):E769-E778. doi: 10.1210/jc.2012-2749.</mixed-citation><mixed-citation xml:lang="en">Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin Is Expressed and Produced by Human Muscle and Adipose Tissue in Association With Obesity and Insulin Resistance. The Journal of Clinical Endocrinology &amp; Metabolism. 2013;98(4):E769-E778. doi: 10.1210/jc.2012-2749.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Shoukry A, Shalaby SM, El-Arabi Bdeer S, et al. Circulating serum irisin levels in obesity and type 2 diabetes mellitus. IUBMB Life. 2016;68(7):544-556. doi: 10.1002/iub.1511.</mixed-citation><mixed-citation xml:lang="en">Shoukry A, Shalaby SM, El-Arabi Bdeer S, et al. Circulating serum irisin levels in obesity and type 2 diabetes mellitus. IUBMB Life. 2016;68(7):544-556. doi: 10.1002/iub.1511.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Provatopoulou X, Georgiou GP, Kalogera E, et al. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics. BMC Cancer. 2015;15(1). doi: 10.1186/s12885-015-1898-1.</mixed-citation><mixed-citation xml:lang="en">Provatopoulou X, Georgiou GP, Kalogera E, et al. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics. BMC Cancer. 2015;15(1). doi: 10.1186/s12885-015-1898-1.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Szydło B, Kiczmer P, Świętochowska E, Ostrowska Z. Role of omentin and chemerin in metabolic syndrome and tumor diseases. Postępy Higieny i Medycyny Doświadczalnej. 2016;70:844-849. doi: 10.5604/17322693.1214137.</mixed-citation><mixed-citation xml:lang="en">Szydło B, Kiczmer P, Świętochowska E, Ostrowska Z. Role of omentin and chemerin in metabolic syndrome and tumor diseases. Postępy Higieny i Medycyny Doświadczalnej. 2016;70:844-849. doi: 10.5604/17322693.1214137.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Esposito K, Chiodini P, Capuano A, et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine. 2013;44(3):634-647. doi: 10.1007/s12020-013-9939-5.</mixed-citation><mixed-citation xml:lang="en">Esposito K, Chiodini P, Capuano A, et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine. 2013;44(3):634-647. doi: 10.1007/s12020-013-9939-5.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Argilés JM, Orpí M, Busquets S, López-Soriano FJ. Myostatin: more than just a regulator of muscle mass. Drug Discovery Today. 2012;17(13-14):702-709. doi: 10.1016/j.drudis.2012.02.001.</mixed-citation><mixed-citation xml:lang="en">Argilés JM, Orpí M, Busquets S, López-Soriano FJ. Myostatin: more than just a regulator of muscle mass. Drug Discovery Today. 2012;17(13-14):702-709. doi: 10.1016/j.drudis.2012.02.001.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Minihane AM, Vinoy S, Russell WR, et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. British Journal of Nutrition. 2015;114(07):999-1012. doi: 10.1017/s0007114515002093.</mixed-citation><mixed-citation xml:lang="en">Minihane AM, Vinoy S, Russell WR, et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. British Journal of Nutrition. 2015;114(07):999-1012. doi: 10.1017/s0007114515002093.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Setiawan VW, Yang HP, Pike MC, et al. Type I and II Endometrial Cancers: Have They Different Risk Factors? Journal of Clinical Oncology. 2013;31(20):2607-2618. doi: 10.1200/jco.2012.48.2596.</mixed-citation><mixed-citation xml:lang="en">Setiawan VW, Yang HP, Pike MC, et al. Type I and II Endometrial Cancers: Have They Different Risk Factors? Journal of Clinical Oncology. 2013;31(20):2607-2618. doi: 10.1200/jco.2012.48.2596.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. American Journal of Obstetrics and Gynecology. 2011;205(6):518-525. doi: 10.1016/j.ajog.2011.05.042.</mixed-citation><mixed-citation xml:lang="en">Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. American Journal of Obstetrics and Gynecology. 2011;205(6):518-525. doi: 10.1016/j.ajog.2011.05.042.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
